These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 25070319)

  • 21. W(h)ither metreleptin for lipodystrophy and the metabolic syndrome?
    Mantzoros CS
    Endocr Pract; 2010; 16(2):162-6. PubMed ID: 20350904
    [No Abstract]   [Full Text] [Related]  

  • 22. The effect of leptin replacement on parathyroid hormone, RANKL-osteoprotegerin axis, and Wnt inhibitors in young women with hypothalamic amenorrhea.
    Foo JP; Polyzos SA; Anastasilakis AD; Chou S; Mantzoros CS
    J Clin Endocrinol Metab; 2014 Nov; 99(11):E2252-8. PubMed ID: 25148234
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rationale for leptin-replacement therapy for severe lipodystrophy.
    Oral EA; Chan JL
    Endocr Pract; 2010; 16(2):324-33. PubMed ID: 20061299
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Facial soft tissue volume decreases during metreleptin treatment in patients with partial and generalized lipodystrophy.
    Miehle K; Stumvoll M; Fasshauer M; Hierl T
    Endocrine; 2017 Nov; 58(2):262-266. PubMed ID: 28993984
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Congenital generalized lipodystrophy type 4 due to a novel PTRF/CAVIN1 pathogenic variant in a child: effects of metreleptin substitution.
    Adiyaman SC; V Schnurbein J; De Laffolie J; Hahn A; Siebert R; Wabitsch M; Kamrath C
    J Pediatr Endocrinol Metab; 2022 Jul; 35(7):946-952. PubMed ID: 35405042
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in bone mineral density, body composition, and lipid metabolism during growth hormone (GH) treatment in children with GH deficiency.
    Boot AM; Engels MA; Boerma GJ; Krenning EP; De Muinck Keizer-Schrama SM
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2423-8. PubMed ID: 9253311
    [TBL] [Abstract][Full Text] [Related]  

  • 27. First metreleptin treatment for generalized lipodystrophy in Turkey.
    Simsir IY; Yurekli BS; Saygili F; Altay C; Akinci B
    Diabetes Obes Metab; 2017 Feb; 19(2):299-301. PubMed ID: 27717125
    [No Abstract]   [Full Text] [Related]  

  • 28. Correlation of Bone Mineral Parameters with Anthropometric Measurements and the Effect of Glucocorticoids on Bone Mineral Parameters in Congenital Adrenal Hyperplasia.
    Ganesh R; Suresh N; Janakiraman L; Ravikumar K
    Indian J Pediatr; 2016 Feb; 83(2):126-30. PubMed ID: 26223873
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Growth hormone improves bone mineral content in children with cystic fibrosis.
    Hardin DS; Ahn C; Prestidge C; Seilheimer DK; Ellis KJ
    J Pediatr Endocrinol Metab; 2005 Jun; 18(6):589-95. PubMed ID: 16042327
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity associated with metreleptin treatment in patients with obesity or lipodystrophy.
    Chan JL; Koda J; Heilig JS; Cochran EK; Gorden P; Oral EA; Brown RJ
    Clin Endocrinol (Oxf); 2016 Jul; 85(1):137-49. PubMed ID: 26589105
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical effects of long-term metreleptin treatment in patients with lipodystrophy.
    Chan JL; Lutz K; Cochran E; Huang W; Peters Y; Weyer C; Gorden P
    Endocr Pract; 2011; 17(6):922-32. PubMed ID: 22068254
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of efficacy and safety of leptin replacement therapy in moderately and severely hypoleptinemic patients with familial partial lipodystrophy of the Dunnigan variety.
    Simha V; Subramanyam L; Szczepaniak L; Quittner C; Adams-Huet B; Snell P; Garg A
    J Clin Endocrinol Metab; 2012 Mar; 97(3):785-92. PubMed ID: 22170723
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Endogenous Leptin Concentrations Poorly Predict Metreleptin Response in Patients With Partial Lipodystrophy.
    Meral R; Malandrino N; Walter M; Neidert AH; Muniyappa R; Oral EA; Brown RJ
    J Clin Endocrinol Metab; 2022 Mar; 107(4):e1739-e1751. PubMed ID: 34677608
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of subcutaneous leptin replacement therapy on bone metabolism in patients with generalized lipodystrophy.
    Simha V; Zerwekh JE; Sakhaee K; Garg A
    J Clin Endocrinol Metab; 2002 Nov; 87(11):4942-5. PubMed ID: 12414854
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of orlistat on bone turnover and body composition.
    Gotfredsen A; Westergren Hendel H; Andersen T
    Int J Obes Relat Metab Disord; 2001 Aug; 25(8):1154-60. PubMed ID: 11486790
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of Metreleptin Treatment in Familial Partial Lipodystrophy Due to PPARG vs LMNA Pathogenic Variants.
    Sekizkardes H; Cochran E; Malandrino N; Garg A; Brown RJ
    J Clin Endocrinol Metab; 2019 Aug; 104(8):3068-3076. PubMed ID: 31194872
    [TBL] [Abstract][Full Text] [Related]  

  • 37. One-year metreleptin improves insulin secretion in patients with diabetes linked to genetic lipodystrophic syndromes.
    Vatier C; Fetita S; Boudou P; Tchankou C; Deville L; Riveline J; Young J; Mathivon L; Travert F; Morin D; Cahen J; Lascols O; Andreelli F; Reznik Y; Mongeois E; Madelaine I; Vantyghem M; Gautier J; Vigouroux C
    Diabetes Obes Metab; 2016 Jul; 18(7):693-7. PubMed ID: 26584826
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metreleptin Treatment in Patients with Non-HIV Associated Lipodystrophy.
    Akinci G; Akinci B
    Recent Pat Endocr Metab Immune Drug Discov; 2015; 9(2):74-8. PubMed ID: 26556498
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fifteen years of GH replacement increases bone mineral density in hypopituitary patients with adult-onset GH deficiency.
    Elbornsson M; Götherström G; Bosæus I; Bengtsson BÅ; Johannsson G; Svensson J
    Eur J Endocrinol; 2012 May; 166(5):787-95. PubMed ID: 22318746
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Leptin treatment reduces body fat but does not affect lean body mass or the myostatin-follistatin-activin axis in lean hypoleptinemic women.
    Brinkoetter M; Magkos F; Vamvini M; Mantzoros CS
    Am J Physiol Endocrinol Metab; 2011 Jul; 301(1):E99-E104. PubMed ID: 21505147
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.